Digital Pulse

Fertility care is beginning to serve as an example of where the next wave of healthcare innovation will be developed. The opportunities for pharmaceutical companies go well beyond the development of new treatments, since AI, digital health platforms and workplace technologies are providing new methods of supporting patients, clinicians and employers throughout what is still a fragmented fertility journey.In the recent episode of the Digital Pulse podcast, host Shubhangi Dua was joined by Clara

Artificial intelligence (AI) is now making waves in the pharmaceutical and life sciences industry. Healthcare leaders are now dealing with the question: How can AI make patient outcomes better without losing sight of the people it’s designed to serve?In the recent episode of Digital Pulse by Pharmatica, host Shubhangi Dua, Podcast Producer and B2B Journalist, sat down with Kate O’Reilly, President and Chair, Board of Directors, Healthcare Businesswomen’s Association Dublin Chapter and Healthcare

Pharma leaders are investing a lot in large language models (LLMs) for issues that a simpler, cheaper machine learning model could handle more quickly and validate with less effort. This is the warning from Lara Masad, an AI and Data Innovation independent consultant, who spoke on the Pharmatica podcast hosted by Shubhangi Dua.The main issue, according to Masad, is that the industry confuses two fundamentally different technologies. "Traditional machine learning models are trained to do one specific

A product receives market authorisation. It is clinically validated, commercially ready, and genuinely needed. Then it waits for a guideline review, cost evaluation, formulary decisions and three years later, it reaches an NHS patient. For pharma executives who have spent a decade developing that product, the timeline is not a surprise. But it is increasingly a choice, not an inevitability.Judit Mora, CEO and co-founder of Nuumad, joined Trisha Pillay on Digital Pulse to make the case that the route

Across many parts of Africa, clinical research still depends heavily on paper-based workflows. For pharmaceutical companies managing global trial portfolios, this can create operational challenges around data quality, monitoring, and regulatory readiness, particularly when studies contribute to submissions in the US and Europe.Adriaan Kruger, founder and CEO of nuvoteQ has spent twelve years building the infrastructure to close that gap. His conversation with Trisha Pillay on Digital Pulse is one of